Abstract
Objective: Surfactant therapy (ST) has significantly reduced mortality and respiratory morbidities among preterm infants with respiratory distress syndrome (RDS). However, majority of late preterm and term infants with respiratory distress also suffer from non-RDS lung diseases. In some of these diseases, secondary surfactant deficiency may develop and ST can be beneficial. In this study we evaluated the indications and early outcomes of ST in late preterm and term infants.
Material and Methods: We retrospectively evaluated the medical records of 135 late preterm and term infants who underwent ST between January 2009 and December 2012. The clinical characteristics of the patients, their diagnoses, number of surfactant application and time of administration, FiO2 requirements before and after ST (1st and 6th hours),duration of mechanical ventilation, and mortality rate were evaluated.
Results: Among135 late preterm and term patients treated with ST, 78 (57.8%) were given ST due to lung disease other than RDS and had longer mechanical ventilator duration. In addition, ≥ 2 doses of surfactant requirement, pulmonary hypertension and mortality rate were found to be higher in these infants. Among patients with RDS, as expected, FiO2requirement was found to decrease in the 1st and 6th hours after ST (0.60 to 0.50 & 0.37 and p <0.001). Sixteen percent of newborns with congenital pneumonia required repeated surfactant doses. The FiO2 requirement after ST was decreased in 42 patients with congenital pneumonia (0.67 to 0.65 & 0.48 and p <0.001). Sixteen patients with severe meconium aspiration syndrome (median FiO2; 0.98) and 25 patients supporting with high frequency oscillatory ventilation (HFOV) support did not benefit from ST (p = 0.71 and p = 0.964).
Conclusion: We observed that ST reduced oxygen requirement in the late preterm and term infants with RDS and congenital pneumonia. However, we found that ST was not beneficial in the infants who applied HFOV due to severe respiratory insufficiency. We think that prospective studies involving a larger number of patients are needed to determine treatment options in these patient groups.
Keywords: Meconium aspiration syndrome, Newborn
References
- Rubaltelli FF, Dani C, Reali MF, Bertini G, Wiechmann L, Tangucci M, et al. Acute neonatal respiratory distress in Italy: a one-year prospective study. Italian Group of Neonatal Pneumology. Acta Paediatr 1998;87:1261-8.
- Horowitz K, Feldman D, Stuart B, Borgida A, Ming Victor Fang Y, Herson V. Full-term neonatal intenstive care unit admission in an urban community hospital: the role of respiratory morbidity. J Matern Fetal Neonatal Med 2011; 24: 1407-10.
- Consortium on Safe Labor, Hibbard JU, Wilkins I, Sun L, Gregory K, Haberman S, Hoffman M, et al. Respiratory morbidity in late preterm births. JAMA 2010; 304: 419-25.
- Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; 2: CD000511.
- Finer NN. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev 2004; 5 Suppl A: 289-97.
- Engle WA; American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419-32.
- D’Angio CT, Sinkin RA, Stevens TP, Landfish NK, Merzbach JL, Ryan RM, et al. Longitudinal, 15- year follow-up of children born at less than 29 weeks gestation after introduction of surfactant therapy into a region: neurologic, cognitive, and educational outcomes. Pediatrics 2002; 110:1094–102.
- Özkan H, Erdeve Ö, Kanmaz Kutman HG, Surfaktan tedavisi. Koç E, Vural M, editors. Türk Neonatoloji Derneği Respiratuvar Distres Sendromu ve Sürfaktan Tedavi Rehberi 2018; 9-10.
- Deshpande S, Suryawanshi P, Ahya K, Maheshwari R, Gupta S. Surfactant therapy for early onset pneumonia in late preterm and term neonates needing mechanical ventilation. J Clin Diagn Res 2017;11: SC09-SC12.
- Fetter WP, Baerts W, Bos AP, van Lingen RA. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 1995; 84: 14-6.
- Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 2000; 106: 957-64.
- Tan K, Lai NM, Sharma A. Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane Database Syst Rev 2012;15: CD008155.
- Vento G, Tana M, Tirone C, Aurilia C, Lio A, Perelli S, et al. Effectiveness of treatment with surfactant in premature infants with respiratory failure and pulmonary infection. Acta Biomed 2012; 83 Suppl 1: 33-6.
- El Shahed AI, Dargaville P, Ohlsson A, Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007;18: CD002054.
- Van Meurs K; Congenital Diaphragmatic Hernia Study Group. Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? J Pediatr 2004;145:312-6.
- Cogo PE, Zimmermann LJ, Verlato G, Midrio P, Gucciardi A, Ori C, et al. A dual stable isotope tracer method for the measurement of surfactant disaturated-phosphatidylcholine net synthesis in infants with congenitaldiaphragmatic hernia. Pediatr Res 2004; 56: 184-90.
- Zani A, Eaton S, Puri P, Rintala R, Lukac M, Bagolan P, et al. EUPSA Network Office. International Survey on the Management of Congenital Diaphragmatic Hernia. Eur J Pediatr Surg 2016; 26: 38-46.
Copyright and license
Copyright © 2020 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
